Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial

Gynecologic Oncology
M MarkmanSamuel S Lentz

Abstract

In an effort to critically examine the antitumor activity of altretamine (hexamethylmelamine) as salvage therapy of platinum-refractory ovarian cancer, the Gynecologic Oncology Group initiated a Phase II trial of the agent administered in this clinical setting. Altretamine was administered at a dose of 260 mg/m2 orally for 14 days in a 28-day course. Treatment was continued until disease progression or unacceptable side effects prevented further therapy. A total of 36 patients (median age: 56.5) were treated on this trial, of whom 33 were evaluable for toxicity and 30 for response. All patients had previously received either cisplatin or carboplatin and paclitaxel. The major side effect was emesis (grade 3-4, 7/33, 21%). The objective response rate was 10% (one complete response, two partial responses). We conclude that altretamine has limited activity in platinum-refractory ovarian cancer.

References

Jan 1, 1990·Gynecologic Oncology·A ManettaP Schein
Oct 15, 1987·Cancer·T ThigpenR McGehee
Nov 1, 1982·Journal of Surgical Oncology·M A Tempero, A Kessinger

❮ Previous
Next ❯

Citations

Apr 17, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·D S AlbertsM L Rothenberg
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David S MillerCecelia H Boardman
Mar 20, 2003·Cancer Investigation·Abbie L Fields, Carolyn D Runowicz
Nov 25, 2003·Cancer Investigation·David M BorutaLinda Van Le
Apr 14, 2009·Gynecologic Oncology·David M GershensonJohn J Kavanagh
Apr 1, 2009·Seminars in Oncology·Lainie P Martin, Russell J Schilder
Apr 10, 2014·Journal of Ovarian Research·Hiroshi KawaguchiMasahide Ohmichi
Feb 19, 2005·Seminars in Oncology·Maurie MarkmanFranco M Muggia
Oct 12, 2007·Expert Opinion on Pharmacotherapy·Susan C Modesitt, Amir A Jazaeri
Oct 5, 2001·Expert Opinion on Pharmacotherapy·E L TrimbleM C Christian
Jan 5, 2002·Expert Opinion on Investigational Drugs·M Harries, S B Kaye
Sep 10, 2003·Hematology/oncology Clinics of North America·Vicki V Baker
Jun 24, 2017·Journal of Natural Medicines·Pornsiri PitchakarnPornngarm Limtrakul
Nov 1, 2001·Clinical Obstetrics and Gynecology·V V Baker
May 6, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Tate ThigpenUNKNOWN Gynecologic Cancer InterGroup
Nov 3, 2006·Nature Clinical Practice. Oncology·Thomas J Herzog, Bhavana Pothuri
Dec 21, 2000·Current Oncology Reports·A A Garcia
Oct 17, 2006·Current Oncology Reports·Thomas J Herzog
Aug 5, 2011·Drugs·R Wendel Naumann, Robert L Coleman
Mar 8, 2000·The Oncologist·M Markman, M A Bookman
Feb 22, 2012·Clinical Obstetrics and Gynecology·Leigh G SeamonLarry J Copeland
May 20, 2017·Expert Opinion on Pharmacotherapy·Federica TomaoPierluigi Benedetti Panici
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas J Herzog
Jul 20, 2019·International Journal of Biological Macromolecules·Ritutama GhoshNand Kishore

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.